ストックスクリーナーアプリを入手
1.735
1.42%
-0.025
Nervgen Pharma Corp (NGEN) 最新ニュース
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
NGEN: RESTORE Phase 3 trial advances with robust funding and FDA alignment; Q2 net loss widens - TradingView
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Caledonian Record
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NervGen Pharma (NGEN) Institutional Ownership 2026 - MarketBeat
NervGen Pharma (NGEN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
NGEN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals Market Sentiment - Benzinga
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nervgen Pharma Ord Shs (NGEN) Balance Sheet - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Income Statement - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.640|Chg%:+0.010 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Cash Flow - TradingKey
NervGen Pharma Corp. Revenue Breakdown – NASDAQ:NGEN - TradingView
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.630|Chg%:-0.045 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NGEN Q3 2025 Earnings: Slight EPS Beat Amid Ongoing Pipeline DevelopmentGAAP Earnings Report - dars.gov.et
Certain Common Shares of NervGen Pharma Corp. are subject to a Lock-Up Agreement Ending on 21-JUL-2026. - marketscreener.com
HC Wainwright Lowers Earnings Estimates for NervGen Pharma - MarketBeat
Stock Ratings | HC Wainwright lowered its price target for NervGen Pharma (NGEN) to $15, with a potential upside of 762.07%; KeyBanc raised its price target for Nvidia (NVDA) to $330 - Sahm
H.C. Wainwright cuts NervGen stock price target to $15 on dilution By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com Nigeria
NGEN Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $15.00 - GuruFocus
NervGen Pharma (NGEN) Gains Ground: Biotech Stock Holds Above Key SupportRelative Volume - dars.gov.et
NGEN Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates NervGen Pharma(NGEN.US) With Buy Rating, Announces Target Price $10 - Moomoo
NervGen Pharma (NASDAQ:NGEN) Now Covered by Leerink Partners - MarketBeat
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed | NGEN Stock News - Quiver Quantitative
If You Invested $1,000 in Nervgen Pharma Corp (NGENF) - Stock Titan
NGEN Q3 2025 Earnings: Narrow EPS Beat Masks Continued Pre-Revenue Stage, Stock Sheds Nearly 7%EPS Consistency Score - dars.gov.et
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial - BioXconomy
NervGen Pharma (NGEN) Q3 2025 Earnings: Small EPS Beat Amid Ongoing Clinical Development and Cash ManagementEarnings Growth Analysis - dars.gov.et
NervGen Pharma(NGEN) Stock Options Chain | Quotes & News - Moomoo
NervGen Pharma Corp. (NGEN) Q3 2025 Earnings: Small EPS Beat as Pipeline Progress Underpins Market ConfidenceOperating Margin Analysis - dars.gov.et
If You Invested $1,000 in Satellos Bioscience Inc (MSCLF) - Stock Titan
NervGen Pharma Corp. (NGEN) Edges Higher: Biotech Stock Tests Support at $2.01 Amid Modest GainsDividend Arbitrage - dars.gov.et
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners - TipRanks
NervGen Pharma remains a Buy after FDA aligns o... - Pluang
NervGen Pharma: I Think The Biggest Risks Are Now Behind It (NASDAQ:NGEN) - Seeking Alpha
NGEN Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseProfit Recovery Report - dars.gov.et
NGEN Q3 2025 Earnings: Narrower Loss Surprises, Stock Advances Amid Pipeline FocusGeographic Revenue Trends - dars.gov.et
Enterprise value to revenue forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to book forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Enterprise value to EBIT forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Enterprise value to EBITDA forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to sales forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
NervGen Pharma Corp. Actuals & Estimates (NASDAQ:NGEN) - TradingView
NGEN Forecast — Price Target — Prediction for 2027 - TradingView
9UA Forecast — Price Target — Prediction for 2027 - TradingView
NervGen Pharma Corp. Actuals & Estimates (FWB:9UA) - TradingView
NervGen Pharma Corp. Actuals & Estimates (DUS:9UA) - TradingView
NervGen rises as TD Cowen issues new BUY on lead asset - MSN
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):